In the Department of Clinical Pharmacology, St Thomas's Hospital, London, I studied glucose tolerance in 21 ocular hypertensives (as defined by Hollows and Graham') and 21 age and sex matched control subjects. Subjects with known diabetes were excluded. Each group contained 14 women and seven men. Ages (years, mean (SD)) were 63-8 (7 3) for ocular hypertensives and 63-1 (8-31) for controls. Testing was performed according to WHO recommendations.6 After a 12 hour overnight fast a venous blood sample was taken and subjects drank 82-5 g hydrous glucose dissolved in 300 ml tap water in less than 5 minutes. A further venous sample was taken 2 hours later. One patient in each group was excluded from final analysis for technical reasons.
Patients were classified as normal glucose tolerance (fasting glucose <6-7 mmol/l, 2 hour glucose <6-7 mmol/1), impaired glucose tolerance (IGT) (fasting glucose <6 7 mmoUl, 2 hour glucose >6-7 mmol/l but <10-0 mmolIl), or diabetes mellitus (DM) (fasting glucose :6-7 mmol/l or 2 hour glucose ,-10-0 mmol/1).
Results (see Table) were analysed by X2 Pleomorphic adenoma of the lacrimal gland EDITOR,-I read with interest the article by Rose and Wright' regarding their recommendations for diagnosis and treatment of pleomorphic adenomas of the lacrimal gland. The authors emphasise that biopsy of these lesions is often associated with recurrence and spread of the tumour, and they recommend against a biopsy in any case suspected ofbeing a pleomorphic adenoma. Although I agree with them that a biopsy of the lesion, followed by termination of surgery with definitive surgery of the tumour at a later date is likely to result in recurrence of the tumour, it is unclear to me whether or not biopsy of the lesion for frozen section diagnosis, followed by definitive treatment of the lesion at the same time has the same probability ofresulting in a recurrent tumour. I
